Examples of using Progressive multiple sclerosis in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Secondary Progressive Multiple Sclerosis European Study.
Evaluate other treatment and simptopmatsku therapy in primary progressive multiple sclerosis.
Primary progressive multiple sclerosis is progressive from the start, bez relapsa.
Your profile can add PMSD framework andthus spread the word about the progressive multiple sclerosis!
Home/ Secondary progressive multiple sclerosis- what is and can be slowed down its development?
Preparing proposals for rational treatment of people with primary progressive multiple sclerosis.
Diagnosis: Secondary progressive multiple sclerosis with cerebrospinal involvement, spastic paraparesis of lower extremities and urine retention.
 It has been1 month since M. was treated at your clinic for Secondary Progressive Multiple Sclerosis.
Identify the profile of patients with primary progressive multiple sclerosis who is currently receiving treatment.
New data at AAN reinforce clinical benefit of Roche's OCREVUS™(ocrelizumab)for relapsing and primary progressive multiple sclerosis.
Rebif has notyet been investigated in patients with primary progressive multiple sclerosis, and should not be used in these patients.
Strengthen data collection on the current patient satisfaction andsystem costs for existing therapies for primary progressive multiple sclerosis.
All patients who participated in this study had progressive multiple sclerosis, which is characterized by that the disease is constantly getting worse without periods of recovery.
OCREVUS may delay the need for a wheelchair by seven years for people with primary progressive multiple sclerosis PPMS.
In a placebo-controlled study with 498 patients suffering from progressive multiple sclerosis THC, which was given for 36 months, had no effect on progression compared to placebo.
This is the first and only drug approved in the European Union(I)to treat patients with early primary progressive multiple sclerosis PPMS.
OKRELIZUMAB- new drugs for primary progressive multiple sclerosis OCREVUS is indicated for the treatment of adult patients with early primary progressive multiple sclerosis(PPMS) in terms of duration of disease and disability, and level with the….
Whilst in the previous stage had better and worse days,in secondary progressive multiple sclerosis symptoms engaging wheel.
It was only in recent clinical study(Oratory) s monoklonalnim protutijelom ocrelizumab-om(modification chimeričkog antibodies- rituximab and a humanized monoclonal antibody ocrelizumab)showed beneficial effects in the eye 23% patients with primary progressive multiple sclerosis.
Roche announces new OCREVUS(ocrelizumab)data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis.
Roche's OCREVUS(ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis andprimary progressive multiple sclerosis.
OCREVUS is indicated for thetreatment of adult patients with early primary progressive multiple sclerosis(PPMS) in terms of disease duration and level of disability, and the features characteristic of the inflammatory activity in the visible imaging examinations.
If approved, OCREVUS will be the first andonly medicine for people in the European Union(EU) with primary progressive multiple sclerosis PPMS.
View Larger Image Rituximab can help in treating secondary progressive multiple sclerosis It appears that administration of rituximab immunotherapeutics can help prevent or delay the complications secondary progressive multiple sclerosis(SPMS), suggests a new study conducted in Switzerland.
Comments Off on The answer of the Minister ofHealth on the availability of a new drug for primary progressive multiple sclerosis in Croatia.
In a 3-year study in patients with secondary progressive multiple sclerosis(EDSS 3-6.5) with evidence of clinical progression in the preceding two years and who had not experienced relapses in the preceding 8 weeks, Rebif had no significant effect on progression of disability, but relapse rate was reduced by approximately 30.
New data at EAN show Roche's OCREVUS(ocrelizumab)significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis.
Additional data presented at the ECTRIMS4 congress in September showed thatRoche's ocrelizumab increased disease control in both relapsing and primary progressive multiple sclerosis RMS and PPMS.
It seems that ibudilast, drug that is in Japan for years used to treat degree and dizziness in Survivors stroke,can slow the decrease in volume in the brain tissue of patients with progressive multiple sclerosis, suggests new study.
According to research at a university hospital near Madrid, Spain, there were significant differences in the distribution of types of the gene that encodes theCB1 receptor in patients suffering from primary progressive multiple sclerosis compared to healthy controls.